Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer.

Tobias Max Philipp HartwichMiranda MansolfCem DemirkiranMichelle GreenmanStefania BelloneBlair McNamaraShuvro P NandiLudmil B AlexandrovYang Yang-HartwichSilvia ComaJonathan PachterAlessandro D Santin

Published in: Cancer medicine (2024)

Avutometinib, defactinib, and to a larger extent their combinations, demonstrated promising in vitro and in vivo activity against EAC cell lines and xenografts. These preclinical data support the potential clinical evaluation of this combination in high-grade EAC patients.

Keyphrases

high grade
endometrial cancer
low grade
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
cell therapy
machine learning
patient reported outcomes
big data
mesenchymal stem cells
climate change
deep learning
patient reported
human health
risk assessment